<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Procedure for intrauterine insemination (IUI) using processed sperm</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Procedure for intrauterine insemination (IUI) using processed sperm</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Procedure for intrauterine insemination (IUI) using processed sperm</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth S Ginsburg, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert L Barbieri, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen Eckler, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 31, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Intrauterine insemination (IUI) is a procedure in which processed and concentrated motile sperm are placed directly into the uterine cavity to increase the likelihood of conception. The procedure is timed with ovulation, which may be natural or a result of ovarian hyperstimulation. The procedure is typically used by patients with sexual dysfunction and certain types of infertility (eg, cervical factor, mild male factor).</p><p>This topic will discuss the details of IUI, including sperm collection, timing of ovulation, and the IUI procedure itself. Related content on infertility is presented separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7396.html" rel="external">"Overview of infertility"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7423.html" rel="external">"Donor insemination"</a>.)</p><p></p><p>In this topic, when discussing study results, we will use the terms "woman/en" or "patient(s)" as they are used in the studies presented. We encourage the reader to consider the specific counseling and treatment needs of transgender and gender-expansive individuals.</p><p class="headingAnchor" id="H2"><span class="h1">DESCRIPTION AND CLINICAL USE</span></p><p class="headingAnchor" id="H2644151144"><span class="h2">Description</span><span class="headingEndMark"> — </span>IUI is based on the hypothesis that placing a large number of sperm high in the reproductive tract enhances the likelihood of conception. The minimum requirements for performing the procedure are ovulation in the IUI cycle, patency of at least one fallopian tube, inseminate with an adequate number of motile sperm, and absence of documented or suspected active cervical, intrauterine, or pelvic infection.</p><p class="headingAnchor" id="H2874802967"><span class="h2">Indications</span><span class="headingEndMark"> — </span>Because coitus can be avoided, IUI is particularly useful in couples with some types of severe sexual dysfunction (eg, severe vaginismus, ejaculatory dysfunction). For cervical factor or mild male factor infertility, IUI allows sperm to bypass potentially hostile cervical factors, thus increasing the number of sperm that gain access to the uterine cavity (and oocyte). For women undergoing ovulation induction, including those with unexplained infertility or minimal or mild endometriosis, pregnancy rates are thought to be higher when IUI is used as an adjunctive procedure instead of timed natural intercourse. In these couples, IUI is often used as an intermediate level and cost-effective intervention prior to proceeding to in vitro fertilization (IVF). The pregnancy rate after IUI depends on male factors, female factors, and technical factors.</p><p>Clinical indications for IUI are discussed in more detail in related content:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7410.html" rel="external">"Unexplained infertility", section on 'Intrauterine insemination (IUI)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7408.html" rel="external">"Endometriosis: Treatment of infertility in females"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7407.html" rel="external">"Overview of ovulation induction"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7394.html" rel="external">"Use of assisted reproduction in HIV- and hepatitis-infected couples"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5448.html" rel="external">"Female infertility: Treatments", section on 'Cervical factor infertility'</a>.)</p><p></p><p class="headingAnchor" id="H1440715656"><span class="h2">Selection of IUI versus IVF</span><span class="headingEndMark"> — </span>IUI is less medically intensive and lower cost compared with in vitro fertilization. However, IVF is typically preferred for patients with tubal factor and/or severe male factor infertility. (See  <a class="medical medical_review" href="/z/d/html/7404.html" rel="external">"In vitro fertilization: Overview of clinical issues and questions"</a>.) </p><p class="headingAnchor" id="H1836697"><span class="h1">SPERM COLLECTION AND PROCESSING</span><span class="headingEndMark"> — </span>IUI is usually performed with fresh sperm from the woman's partner. IUI with donor sperm, which is frozen, is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7423.html" rel="external">"Donor insemination"</a>.)</p><p class="headingAnchor" id="H1836744"><span class="h2">Semen collection</span><span class="headingEndMark"> — </span>We ask men to produce a semen specimen in the morning after two or three days of sexual abstinence [<a href="#rid1">1,2</a>]. The specimen is produced by masturbation, ideally in a private room designated for this purpose in the laboratory/office. The entire ejaculate is collected in a <strong>sterile</strong> cup to minimize the risk of uterine infection from contaminants. We advise avoidance of lubricants, as most are toxic to sperm [<a href="#rid3">3,4</a>]. If a lubricant is needed, we instruct the client to prevent contact between the lubricant and glans.</p><p class="headingAnchor" id="H1836751"><span class="h2">Sperm processing</span><span class="headingEndMark"> — </span>It is critical to separate sperm in the ejaculate from prostaglandin-rich prostatic secretions and seminal fluid, which can cause uterine cramping and, rarely, anaphylaxis, when placed directly into the uterine cavity. In addition, sperm preparation maximizes the number of motile sperm for insemination, removes cellular debris, and concentrates the specimen. </p><p>Two commonly employed techniques for sperm processing are the "swim up" method and use of "density gradient centrifugation." A systematic review of randomized trials comparing these two techniques did not find a statistically significant difference in pregnancy rates [<a href="#rid5">5</a>] . However, the percentage of motile sperm recovered after processing is generally higher with density gradient centrifugation than with the swim up technique [<a href="#rid6">6</a>]. Therefore, we prefer this method in men with oligo- or asthenospermia.</p><p>We evaluate a tiny drop of the processed sample prior to insemination to ensure that an adequate number of moving sperm has been recovered. The minimum post-wash total motile sperm count for IUI is controversial [<a href="#rid7">7,8</a>]. Although pregnancies from IUI have occurred with a post-wash total motile sperm count less than 5 million, a count greater than 5 to 10 million is associated with higher pregnancy rates [<a href="#rid9">9-12</a>]. A count less than this warrants further evaluation and possible treatment by a urologist. If samples consistently have less than 3 to 5 million motile sperm, pregnancy rates will be less than 1 percent per cycle. In these cases, in vitro fertilization (IVF), possibly with intracytoplasmic sperm injection (ICSI), is the appropriate course of treatment to overcome severe male factor infertility.</p><p class="headingAnchor" id="H12812919"><span class="h1">LABORATORY REQUIREMENTS AND TESTING</span><span class="headingEndMark"> — </span>Guidelines govern the management, operation, and accreditation of andrology laboratories [<a href="#rid13">13-17</a>]. One <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.asrm.org%2Fpractice-guidance%2Fpractice-committee-documents%2Fcomprehensive-guidance-for-human-embryology-andrology-and-endocrinology-laboratories-management-and-operations-a-committee-opinion-2022%2F%3F_t_id%3DU7NLRvKawVVVEqJ5qA1pPA%3D%3D%26_t_uuid%3DXzAO0frDTVS8ZJloCfuP6w%26_t_q%3Dlaboratory%26_t_tags%3Dsiteid%3A01216f06-3dc9-4ac9-96da-555740dd020c%2Clanguage%3Aen%2Candquerymatch%26_t_hit.id%3DASRM_Models_Pages_ContentPage%2F_1affb60f-0433-4c57-b6eb-f03ae51a68ff_en%26_t_hit.pos%3D1&amp;token=Pjk3bUFHmM3YROd%2B47sTG86T28NbtbvndiB49Q3IPrsOCt3gPx2UcicpVzvEYsDgIzbFFoc9gh9%2FdKsMZ5VPcHCGK%2FaGbD7O29GmdAr1W5UDHvvYcgM%2FBs4rjy5kMl1DA5t3JIRsQcJ1tzcrc9Iy5BjtLqkYHynD%2FeGK6Wi3VrDidrBX%2BuoeMeh%2FDjKi2I53WfsOojiEJgEOSawdGpS9ifoWlr5%2F1CfNwabkNW4%2FlTA7mV1jY40RQT8Rccwwn%2Fl0pfGJBEO%2BnvBSoQqCE9bm46vSbmLVMWjKV0Lq0GY6y6qEujHmhQvkiKL6RSKjRYRoIzno%2BopaZOcwJppmE7kaRtK1iRpw9D4yOWjJvXRozfYfNNjO7NNlkPIxGW7HRpIZ6KZPpRFynEBf1t8ZchRjeVLIPoEDawiAzICLEP3ET8oqosOVGXSKMxOklNwgSW%2FV&amp;TOPIC_ID=7413" target="_blank">example</a> is available through the American Society for Reproductive Medicine [<a href="#rid13">13</a>]. The requirements and testing of sperm for donor insemination is presented in related content. (See  <a class="medical medical_review" href="/z/d/html/7423.html" rel="external">"Donor insemination", section on 'Donor evaluation'</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">TIMING THE INSEMINATION</span></p><p class="headingAnchor" id="H2214062397"><span class="h2">Detection of ovulation</span><span class="headingEndMark"> — </span>The timing of ovulation is commonly predicted by detection of a luteinizing hormone (LH) surge using either blood or urine. LH surge can be detected in serum starting 36 hours before ovulation; serum and urine LH levels peak approximately 24 hours before ovulation. Urine testing minimizes disruption of the patient's life and is as effective as blood LH testing for IUI timing. The IUI is performed the day after the LH surge, which is the day of ovulation. The oocyte can be fertilized up to 24 hours after ovulation; sperm are most capable of fertilization up to 48 hours after entering the female genital tract. Timing the IUI is based on these relationships. </p><p>An alternate approach includes ultrasound monitoring of ovarian follicle size and injection of exogenous human chorionic gonadotropin (hCG) to trigger follicular maturation and rupture, which occurs approximately 36 hours after administration. In contrast to urine LH testing, ultrasound monitoring requires visits to a clinical site, which may limit the utility of this approach given. A meta-analysis including 13 studies reported similar pregnancy rates between the two approaches (odds ratio [OR] 0.92, 95% CI 0.69-1.22) [<a href="#rid18">18</a>]. Similar pregnancy rates were also reported for the techniques in the subgroup analyses of natural cycle IUI and ovarian stimulation IUI. </p><p class="headingAnchor" id="H2982876194"><span class="h2">Timing of IUI procedure</span><span class="headingEndMark"> — </span>The optimum time for IUI is controversial [<a href="#rid19">19-23</a>]. A 2010 systematic review of trials that evaluated the effectiveness of different synchronization methods in natural and stimulated cycles for IUI in subfertile couples concluded the choice should be based on hospital facilities, convenience for the patient, medical staff, costs and drop-out levels as no method was clearly superior to another [<a href="#rid19">19</a>]. </p><p class="headingAnchor" id="H6"><span class="h2">Unstimulated cycles</span><span class="headingEndMark"> — </span>Natural (unstimulated) cycle procedures are most appropriate for patients with ejaculatory dysfunction, vaginismus, or cervical factor infertility or for individuals using IUI to achieve pregnancy in absence of fertility issues (eg, same-sex couples). Ovulation should be documented prior to proceeding with the unstimulated (natural) cycle IUI. The most cost-effective method is use of an over-the-counter urine ovulation predictor kit. Once the LH surge is documented in first morning urine, IUI is performed the next day. A large randomized trial showed that ovulation monitoring resulted in higher pregnancy rates than human chorionic gonadotropin (hCG) triggering to time insemination in natural cycles [<a href="#rid24">24</a>].</p><p>In our experience, couples are nearly always able to arrange their schedules to allow IUI timed by urinary LH monitoring. In many offices, male partners drop semen samples in the office between 7:00 and 8:30 AM, with IUI processing performed subsequently. Processed sperm can be incubated without significant loss of motility for many hours. The use of LH for timing ovulation in natural cycles actually might be the best way to maximize the probability of pregnancy for patients undergoing IUI. In a randomized trial of <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">clomiphene</a> citrate with IUI, pregnancy rates were higher with urinary LH surge monitoring than with hCG-timed IUI [<a href="#rid24">24</a>].</p><p>In the United States, several types of health care professionals (eg, physician, nurse, nurse practitioner, etc) are permitted to perform and/or bill for IUIs, but this varies from state to state as well as by country.</p><p class="headingAnchor" id="H7"><span class="h2">Stimulated cycles</span><span class="headingEndMark"> — </span>Controlled ovarian hyperstimulation is commonly used with IUI for treatment of infertility in couples with unexplained infertility. <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">Clomiphene</a> citrate is the standard first-line therapy; if unsuccessful, the aromatase inhibitor <a class="drug drug_general" data-topicid="10064" href="/z/d/drug information/10064.html" rel="external">letrozole</a>, injectable gonadotropins, or IVF can be the next step [<a href="#rid25">25</a>]. Letrozole may be preferable to gonadotropins because of the lower cost, ease of use, and lower risk of multiple gestations, particularly triplet gestations or higher [<a href="#rid26">26,27</a>]. Data on the use of aromatase inhibitors with IUI are not extensive, but trial data suggest that letrozole yields equivalent pregnancy rates as clomiphene citrate in combination with IUI in unexplained infertility [<a href="#rid26">26,28</a>]. In a trial by the Reproductive Medicine Network (RMN) without IUI, letrozole was superior to clomiphene for treating anovulatory infertility in patients with polycystic ovary syndrome [<a href="#rid29">29</a>].</p><p>In four randomized trials of patients with unexplained subfertility, pregnancy rates were higher when IUI was performed in stimulated cycles than in natural cycles (odds ratio [OR] 2.14, 95% CI 1.26-3.61; 25 versus 14 percent; 26 patients received <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">clomiphene</a> citrate, 370 patients received gonadotropins) [<a href="#rid30">30</a>]. However, another randomized trial in couples with unexplained infertility found that in vitro fertilization (IVF) resulted in the highest pregnancy rate (per cycle pregnancy rate with IVF 31 percent; per cycle pregnancy rate with clomiphene/IUI and follicle-stimulating hormone [FSH]/IUI cycles 8 and 10 percent, respectively) [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/z/d/html/7407.html" rel="external">"Overview of ovulation induction"</a>.)</p><p class="headingAnchor" id="H1841952"><span class="h3">Clomiphene citrate</span><span class="headingEndMark"> — </span>For most women, our first-line approach for ovarian stimulation is <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">clomiphene</a> citrate (CC) 100 mg for five consecutive days beginning on cycle day 3 or 5, depending on the woman's natural cycle length. <a class="drug drug_general" data-topicid="10064" href="/z/d/drug information/10064.html" rel="external">Letrozole</a> 5 mg for five consecutive days, days 3 through 7, may also be used [<a href="#rid26">26</a>]. Urine LH testing starts on cycle day 10 to 12. Detailed instructions on when to begin LH testing are included in the ovulation predictor kits. Once an LH surge is documented in the first morning urine, IUI is performed the next day. For women who are known to be ovulatory but unable to identify the LH surge with a urine kit, we prescribe CC 100 mg for five consecutive days beginning on cycle day 3 or 5 as above, and then perform <strong>serum</strong> LH testing starting cycle day 12.</p><p>For women undergoing CC ovarian stimulation, higher pregnancy rates have been reported when IUI is performed following spontaneous ovulation as documented by LH surge compared with IUI following hCG injection to trigger ovulation. In a meta-analysis of seven studies including over 2500 women, women who received IUI after hCG injection had a 25 percent reduction in clinical pregnancy rates compared with women who had IUI after LH surge (OR 0.74, 95% CI 0.57-0.96) [<a href="#rid32">32</a>]. Additionally, follicle monitoring with ultrasound and hCG triggering of ovulation increases the patient's visit burden and cost, and therefore is rarely performed in place of CC therapy in our practice. We reserve ultrasound monitoring of the ovarian follicles for women in whom a serum LH is missed.</p><p>For women who do not tolerate or respond to <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">clomiphene</a> and women with unexplained infertility, the aromatase inhibitor <a class="drug drug_general" data-topicid="10064" href="/z/d/drug information/10064.html" rel="external">letrozole</a> can be a second line option for ovarian stimulation [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/z/d/html/7410.html" rel="external">"Unexplained infertility", section on 'Aromatase inhibitors plus IUI'</a>.)</p><p class="headingAnchor" id="H1841975"><span class="h3">Gonadotropin and hCG</span><span class="headingEndMark"> — </span>For older women and younger women with diminished ovarian reserve, we induce ovulation with injectable gonadotropins rather than <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">clomiphene</a> [<a href="#rid33">33,34</a>] or we perform IVF [<a href="#rid31">31</a>]. Injectable gonadotropins (recombinant FSH) are given per provider dosing preference beginning on cycle day 2 or 3. It is the standard of care to follow serum estradiol levels and ovarian follicle size with transvaginal ultrasounds. When at least one follicle has a mean diameter of 15 to 18 mm, the patient self-administers 5000 to 10,000 units of hCG as a subcutaneous or intramuscular injection to trigger ovulation. The minimum size (15 to 23 mm) of the leading follicle before hCG injection is controversial [<a href="#rid35">35-38</a>]. One IUI is performed 36 hours after hCG injection. (See  <a class="medical medical_review" href="/z/d/html/7407.html" rel="external">"Overview of ovulation induction", section on 'Gonadotropin therapy'</a>.)</p><p>The addition of a gonadotropin releasing hormone (GnRH) antagonist to recombinant FSH during controlled ovarian stimulation may improve pregnancy rates by reducing the incidence of premature luteinization in women with some types of ovulatory dysfunction [<a href="#rid39">39,40</a>]. Alternatively, a GnRH antagonist can be added to the controlled ovarian stimulation cycle when the lead follicle is 14 mm in size. This delays luteinization, thus allowing development of additional follicles, which is particularly useful if only one follicle has developed. Use of GnRH antagonists may also be beneficial in preventing luteinization when IUI is delayed over a weekend or holiday in practices with staffing restrictions [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/z/d/html/7410.html" rel="external">"Unexplained infertility", section on 'Gonadotropin injections with or without IUI'</a>.)</p><p class="headingAnchor" id="H14"><span class="h1">IUI PROCEDURE</span></p><p class="headingAnchor" id="H15"><span class="h2">Equipment</span></p><p class="bulletIndent1"><span class="glyph">●</span>Prepared sperm specimen</p><p class="bulletIndent1"><span class="glyph">●</span>Speculum</p><p class="bulletIndent1"><span class="glyph">●</span>1 cc sterile syringe with blunt cannula</p><p class="bulletIndent1"><span class="glyph">●</span>Disposable polyethylene insemination catheter</p><p></p><p class="headingAnchor" id="H16"><span class="h2">Patient preparation</span><span class="headingEndMark"> — </span>Proper identification of both the patient and sperm sample in the laboratory and the clinic is essential. Antibiotic prophylaxis is unnecessary. <a class="drug drug_general" data-topicid="9801" href="/z/d/drug information/9801.html" rel="external">Povidone iodine</a> should not be used to cleanse the cervix because it is toxic to sperm.</p><p class="headingAnchor" id="H17"><span class="h2">Technique</span><span class="headingEndMark"> — </span>We perform a single IUI the day after a urinary LH surge.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Single versus double IUI</strong> – Double IUI is of unclear benefit and increases the number of patient visits, cost, and, potentially, stress.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pregnancy rate – In a meta-analysis of 15 trials, there were no differences in clinical pregnancy rates between women who underwent single versus double IUI (relative risk 1.22, 95% CI 0.97-1.54, 15 trials, 3795 women) [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Live birth rate – A different meta-analysis reported similar live birth rates for double compared with single IUI (odds ratio [OR] 1.15, 95% CI 0.71-1.88, 3 studies, 468 participants), although the source data was deemed to be of low quality [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Our approach</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Obtain fresh or frozen ejaculate for IUI preparation and processing (see <a class="local">'Sperm collection and processing'</a> above). Once processed, care should be taken to maintain the specimen at body temperature until insemination.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The patient should undress from the waist down and lie on an examination table in dorsal lithotomy position with her feet in stirrups. Although not mandatory, consider asking women with an anteverted uterus to maintain a full bladder to facilitate straightening of the uterus. This is not useful for women with retroverted uteri.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Open a 1-cc syringe and draw up approximately 0.3 to 0.5 mL of air.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Attach a blunt sterile needle (eg, MONOJECT blunt cannula).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Aspirate the processed sperm and its suspension media into the syringe. Ideally, the sperm is suspended in a small volume of media, no more than 0.5 mL, to prevent expulsion or reflux from the cervix and uterine contractions after it is inseminated into the uterus.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Attach the syringe to an 18 cm polyethylene insemination catheter. Two types of catheters are available: (1) relatively rigid single sheath catheters (straight or with a preformed curve) that cannot be bent and (2) double sheath catheters with an external flexible sheath that will maintain a curve and a very soft internal catheter. In a 2010 meta-analysis of six randomized trials, pregnancy and live birth rates were the same for flexible and rigid catheters [<a href="#rid44">44</a>]. However, other factors should be considered. We prefer a soft flexible catheter, as it can be formed to accommodate the curve of the patient's uterus and is less traumatic to the endometrium. An internal wire or rigid stylet may be used with the external sheath for difficult IUIs. If it is difficult to pass the IUI catheter through the internal os, transabdominal ultrasound guidance with the patient having a full bladder may be helpful. In our experience, patients barely feel the IUI procedure with these catheters. Stiffer catheters are easier to insert into the uterine cavity because they do not bend, but they are more uncomfortable for the patient and more traumatic to the endometrium, and thus associated with more vaginal bleeding [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Insert the speculum to obtain adequate visualization of the cervix.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Without touching the end of the catheter that will enter the sterile uterine cavity, insert the catheter through the cervical os, through the endocervical canal, and into the uterus to a depth of approximately 6 to 6.5 cm. Try not to let the catheter touch the fundus, as this will cause cramping and, in some cases, disruption of the endometrium and bleeding, which is toxic to embryo development. If difficulty is encountered with insertion of the catheter, use of a rigid stylet or abdominal ultrasound guidance may be helpful. We avoid use of a tenaculum because it causes uterine contractions and patient discomfort.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Inject the sperm and then slowly withdraw the catheter.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sperm are present in the fallopian tubes as early as five minutes after insemination [<a href="#rid46">46</a>]. We have our patients rest in supine or reverse Trendelenburg position for 10 minutes after sperm injection. Although only limited data are available on whether rest is of any value in enhancing pregnancy fertilization rates, one randomized trial reported higher pregnancy rates in rested patients compared with those who were immediately mobile post-IUI (pregnancy rate 16/55 [25 percent] versus 4/40 [10 percent]) [<a href="#rid47">47</a>]. However, a subsequent trial with nearly 500 women reported no difference in ongoing pregnancy rates among women who were immobilized for 15 minutes following IUI and those who were not [<a href="#rid48">48</a>]. Psychologically, patients are often reassured by a period of rest following the procedure.</p><p></p><p class="headingAnchor" id="H18"><span class="h2">Postprocedure care</span><span class="headingEndMark"> — </span>The patient may resume her normal activities after insemination. Increased wetness after the procedure is due to loosened and watery cervical mucus, it does not mean the sperm specimen has flowed out; patients should be reassured about this. Abdominal cramping or discomfort may occur; we suggest <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> if the patient requests treatment. Light bleeding or spotting may also occur.</p><p>Patients may have intercourse after IUI if they wish to do so. However, patients who have pelvic discomfort due to ovarian enlargement from <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">clomiphene</a> or gonadotropins should avoid intercourse. A urinary or serum pregnancy test is performed two weeks after IUI. If the patient has received human chorionic gonadotropin (hCG) for ovulatory triggering, it is important to inform the patient that a urinary or serum pregnancy test may remain positive up to 12 days after the injection.</p><p>A systematic review of randomized trials of vaginal <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> luteal support after ovulation induction/IUI found a higher live birth rate with progesterone support compared with no progesterone support (odds ratio [OR] 2.11, 95% CI 1.21-3.67, three trials, 1196 cycles) [<a href="#rid49">49</a>]. In subgroup analysis, the benefit was restricted to gonadotropin-stimulated cycles. The authors did not perform a subgroup analysis based on baseline characteristics of the subjects. We do not use luteal progesterone in clomiphene-induced cycles, but give luteal vaginal progesterone support in women with a luteal phase &lt;10 days. (See  <a class="medical medical_review" href="/z/d/html/5444.html" rel="external">"Recurrent pregnancy loss: Management", section on 'Progesterone'</a>.)</p><p class="headingAnchor" id="H490451496"><span class="h1">INTRAVAGINAL INSEMINATION</span><span class="headingEndMark"> — </span>Intravaginal insemination is a low-cost, low-resource alternative to IUI that is sometimes used by couples who are unable to have, or choose to avoid, vaginal intercourse (<a class="graphic graphic_table graphicRef89077" href="/z/d/graphic/89077.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H19"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>Upper genital tract infection is a rare potential complication. It is unclear whether the risk of ectopic pregnancy is increased compared with women with similar risk factors for ectopic pregnancy who become pregnant without IUI.</p><p>Ovarian hyperstimulation syndrome is a complication of ovulation induction, but it is usually only observed in exogenous gonadotropin cycles following administration of human chorionic gonadotropin (hCG) or after administration of gonadotropin releasing hormone (GnRH) agonist; it rarely occurs in women treated with <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">clomiphene</a> citrate. (See  <a class="medical medical_review" href="/z/d/html/7401.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of ovarian hyperstimulation syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/7412.html" rel="external">"Prevention of ovarian hyperstimulation syndrome"</a>.)</p><p>The risk of multiple gestation, especially high order multiple gestation, is significantly increased with IUI after superovulation induced by gonadotropins. The risk is much lower with <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">clomiphene</a> citrate. </p><p class="headingAnchor" id="H61118149"><span class="h1">NUMBER OF IUI CYCLES</span><span class="headingEndMark"> — </span>Pregnancy rates are significantly lower after the third IUI cycle, irrespective of the ovulation induction method [<a href="#rid50">50</a>]. At that point, we generally move on to more aggressive treatment. European guidelines (Denmark, England, Wales, France, the Netherlands) suggest three to six IUIs, depending on the cause of infertility [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H20"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/8418.html" rel="external">"Patient education: Infertility treatment with gonadotropins (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H21"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – Intrauterine insemination (IUI) alone is a useful technique for achieving pregnancy in couples with severe sexual dysfunction, but can also be useful in patients with cervical factor infertility as long as at least one fallopian tube is patent. (See <a class="local">'Description and clinical use'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing</strong> – When IUI is performed during an unstimulated (natural cycle) or a <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">clomiphene</a> or <a class="drug drug_general" data-topicid="10064" href="/z/d/drug information/10064.html" rel="external">letrozole</a> stimulated cycle, we suggest use of an over-the-counter ovulation predictor kit to schedule the optimum time for the procedure. (See <a class="local">'Timing the insemination'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ovarian hyperstimulation</strong> – For patients with mild male factor, early stage endometriosis, or unexplained infertility, we suggest controlled ovarian hyperstimulation with IUI rather than natural cycle IUI (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>) (see <a class="local">'Stimulated cycles'</a> above). Ovarian stimulation may employ <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">clomiphene</a> or gonadotropins.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preference for single IUI</strong> – For women undergoing IUI, we recommend a single IUI procedure (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). When compared with double IUI, single IUI has the same efficacy with fewer visits and lower cost.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Semen processing</strong> – Semen processing for IUI is not difficult to learn and can be adapted to use in clinical offices, but care must be taken to ensure that adequate quality measures are in place. (See <a class="local">'Sperm collection and processing'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Jurema MW, Vieira AD, Bankowski B, et al. Effect of ejaculatory abstinence period on the pregnancy rate after intrauterine insemination. Fertil Steril 2005; 84:678.</a></li><li><a class="nounderline abstract_t">Marshburn PB, Alanis M, Matthews ML, et al. A short period of ejaculatory abstinence before intrauterine insemination is associated with higher pregnancy rates. Fertil Steril 2010; 93:286.</a></li><li><a class="nounderline abstract_t">Agarwal A, Deepinder F, Cocuzza M, et al. Effect of vaginal lubricants on sperm motility and chromatin integrity: a prospective comparative study. Fertil Steril 2008; 89:375.</a></li><li><a class="nounderline abstract_t">Anderson L, Lewis SE, McClure N. The effects of coital lubricants on sperm motility in vitro. Hum Reprod 1998; 13:3351.</a></li><li><a class="nounderline abstract_t">Boomsma CM, Cohlen BJ, Farquhar C. Semen preparation techniques for intrauterine insemination. Cochrane Database Syst Rev 2019; 10:CD004507.</a></li><li><a class="nounderline abstract_t">Morshedi M, Duran HE, Taylor S, Oehninger S. Efficacy and pregnancy outcome of two methods of semen preparation for intrauterine insemination: a prospective randomized study. Fertil Steril 2003; 79 Suppl 3:1625.</a></li><li><a class="nounderline abstract_t">Pasqualotto EB, Daitch JA, Hendin BN, et al. Relationship of total motile sperm count and percentage motile sperm to successful pregnancy rates following intrauterine insemination. J Assist Reprod Genet 1999; 16:476.</a></li><li><a class="nounderline abstract_t">van Weert JM, Repping S, Van Voorhis BJ, et al. Performance of the postwash total motile sperm count as a predictor of pregnancy at the time of intrauterine insemination: a meta-analysis. Fertil Steril 2004; 82:612.</a></li><li><a class="nounderline abstract_t">Van Voorhis BJ, Barnett M, Sparks AE, et al. Effect of the total motile sperm count on the efficacy and cost-effectiveness of intrauterine insemination and in vitro fertilization. Fertil Steril 2001; 75:661.</a></li><li><a class="nounderline abstract_t">Miller DC, Hollenbeck BK, Smith GD, et al. Processed total motile sperm count correlates with pregnancy outcome after intrauterine insemination. Urology 2002; 60:497.</a></li><li><a class="nounderline abstract_t">Huang HY, Lee CL, Lai YM, et al. The impact of the total motile sperm count on the success of intrauterine insemination with husband's spermatozoa. J Assist Reprod Genet 1996; 13:56.</a></li><li><a class="nounderline abstract_t">Wainer R, Albert M, Dorion A, et al. Influence of the number of motile spermatozoa inseminated and of their morphology on the success of intrauterine insemination. Hum Reprod 2004; 19:2060.</a></li><li><a class="nounderline abstract_t">Practice Committees of the American Society for Reproductive Medicine (ASRM) and the Society for Reproductive Biologists and Technologists (SRBT). Electronic address: <span class="__cf_email__" data-cfemail="1a7b6968775a7b6968773475687d">[email protected]</span>. Comprehensive guidance for human embryology, andrology, and endocrinology laboratories: management and operations: a committee opinion. Fertil Steril 2022; 117:1183.</a></li><li><a class="nounderline abstract_t">ESHRE Clinic PI Working Group, Vlaisavljevic V, Apter S, et al. The Maribor consensus: report of an expert meeting on the development of performance indicators for clinical practice in ART. Hum Reprod Open 2021; 2021:hoab022.</a></li><li><a class="nounderline abstract_t">ESHRE Special Interest Group of Embryology, Alpha Scientists in Reproductive Medicine. The Vienna consensus: report of an expert meeting on the development of art laboratory performance indicators. Hum Reprod Open 2017; 2017:hox011.</a></li><li class="breakAll">Reproductive Accreditation Program. College of American Pathologists. 2023 https://www.cap.org/laboratory-improvement/accreditation/reproductive-accreditation-program (Accessed on July 28, 2023).</li><li class="breakAll">WHO laboratory manual for the examination and processing of human semen, Sixth edition. World Health Organization. July 2021. https://www.who.int/publications/i/item/9789240030787 (Accessed on July 28, 2023).</li><li><a class="nounderline abstract_t">Potapragada NR, Babayev E, Strom D, et al. Intrauterine Insemination After Human Chorionic Gonadotropin Trigger or Luteinizing Hormone Surge: A Meta-analysis. Obstet Gynecol 2023; 142:61.</a></li><li><a class="nounderline abstract_t">Cantineau AE, Janssen MJ, Cohlen BJ. Synchronised approach for intrauterine insemination in subfertile couples. Cochrane Database Syst Rev 2010; :CD006942.</a></li><li><a class="nounderline abstract_t">Osuna C, Matorras R, Pijoan JI, Rodríguez-Escudero FJ. One versus two inseminations per cycle in intrauterine insemination with sperm from patients' husbands: a systematic review of the literature. Fertil Steril 2004; 82:17.</a></li><li><a class="nounderline abstract_t">Bagis T, Haydardedeoglu B, Kilicdag EB, et al. Single versus double intrauterine insemination in multi-follicular ovarian hyperstimulation cycles: a randomized trial. Hum Reprod 2010; 25:1684.</a></li><li><a class="nounderline abstract_t">Rahman SM, Karmakar D, Malhotra N, Kumar S. Timing of intrauterine insemination: an attempt to unravel the enigma. Arch Gynecol Obstet 2011; 284:1023.</a></li><li><a class="nounderline abstract_t">Tonguc E, Var T, Onalan G, et al. Comparison of the effectiveness of single versus double intrauterine insemination with three different timing regimens. Fertil Steril 2010; 94:1267.</a></li><li><a class="nounderline abstract_t">Kyrou D, Kolibianakis EM, Fatemi HM, et al. Spontaneous triggering of ovulation versus HCG administration in patients undergoing IUI: a prospective randomized study. Reprod Biomed Online 2012; 25:278.</a></li><li><a class="nounderline abstract_t">Dankert T, Kremer JA, Cohlen BJ, et al. A randomized clinical trial of clomiphene citrate versus low dose recombinant FSH for ovarian hyperstimulation in intrauterine insemination cycles for unexplained and male subfertility. Hum Reprod 2007; 22:792.</a></li><li><a class="nounderline abstract_t">Diamond MP, Legro RS, Coutifaris C, et al. Letrozole, Gonadotropin, or Clomiphene for Unexplained Infertility. N Engl J Med 2015; 373:1230.</a></li><li><a class="nounderline abstract_t">Huang S, Wang R, Li R, et al. Ovarian stimulation in infertile women treated with the use of intrauterine insemination: a cohort study from China. Fertil Steril 2018; 109:872.</a></li><li><a class="nounderline abstract_t">Badawy A, Elnashar A, Totongy M. Clomiphene citrate or aromatase inhibitors for superovulation in women with unexplained infertility undergoing intrauterine insemination: a prospective randomized trial. Fertil Steril 2009; 92:1355.</a></li><li><a class="nounderline abstract_t">NIH/NICHD Reproductive Medicine Network. Fertility and Infertility Branch, Eunice Kennedy Shriver. Effect of letrozole versus clomiphene on live birth in women with anovulatory infertility due to PCOS: a randomized double-blind multicenter trial. Fertil Steril 2013; 100:S51.</a></li><li><a class="nounderline abstract_t">Veltman-Verhulst SM, Cohlen BJ, Hughes E, Heineman MJ. Intra-uterine insemination for unexplained subfertility. Cochrane Database Syst Rev 2012; :CD001838.</a></li><li><a class="nounderline abstract_t">Reindollar RH, Regan MM, Neumann PJ, et al. A randomized clinical trial to evaluate optimal treatment for unexplained infertility: the fast track and standard treatment (FASTT) trial. Fertil Steril 2010; 94:888.</a></li><li><a class="nounderline abstract_t">Kosmas IP, Tatsioni A, Fatemi HM, et al. Human chorionic gonadotropin administration vs. luteinizing monitoring for intrauterine insemination timing, after administration of clomiphene citrate: a meta-analysis. Fertil Steril 2007; 87:607.</a></li><li><a class="nounderline abstract_t">Matorras R, Diaz T, Corcostegui B, et al. Ovarian stimulation in intrauterine insemination with donor sperm: a randomized study comparing clomiphene citrate in fixed protocol versus highly purified urinary FSH. Hum Reprod 2002; 17:2107.</a></li><li><a class="nounderline abstract_t">Matorras R, Osuna C, Exposito A, et al. Recombinant FSH versus highly purified FSH in intrauterine insemination: systematic review and metaanalysis. Fertil Steril 2011; 95:1937.</a></li><li><a class="nounderline abstract_t">Ghosh C, Buck G, Priore R, et al. Follicular response and pregnancy among infertile women undergoing ovulation induction and intrauterine insemination. Fertil Steril 2003; 80:328.</a></li><li><a class="nounderline abstract_t">Silverberg KM, Olive DL, Burns WN, et al. Follicular size at the time of human chorionic gonadotropin administration predicts ovulation outcome in human menopausal gonadotropin-stimulated cycles. Fertil Steril 1991; 56:296.</a></li><li><a class="nounderline abstract_t">Palatnik A, Strawn E, Szabo A, Robb P. What is the optimal follicular size before triggering ovulation in intrauterine insemination cycles with clomiphene citrate or letrozole? An analysis of 988 cycles. Fertil Steril 2012; 97:1089.</a></li><li><a class="nounderline abstract_t">Farhi J, Orvieto R, Gavish O, Homburg R. The association between follicular size on human chorionic gonadotropin day and pregnancy rate in clomiphene citrate treated polycystic ovary syndrome patients. Gynecol Endocrinol 2010; 26:546.</a></li><li><a class="nounderline abstract_t">Bakas P, Konidaris S, Liapis A, et al. Role of gonadotropin-releasing hormone antagonist in the management of subfertile couples with intrauterine insemination and controlled ovarian stimulation. Fertil Steril 2011; 95:2024.</a></li><li><a class="nounderline abstract_t">Gómez-Palomares JL, Acevedo-Martín B, Chávez M, et al. Multifollicular recruitment in combination with gonadotropin-releasing hormone antagonist increased pregnancy rates in intrauterine insemination cycles. Fertil Steril 2008; 89:620.</a></li><li><a class="nounderline abstract_t">Checa MA, Prat M, Robles A, Carreras R. Use of gonadotropin-releasing hormone antagonists to overcome the drawbacks of intrauterine insemination on weekends. Fertil Steril 2006; 85:573.</a></li><li><a class="nounderline abstract_t">Arab-Zozani M, Nastri CO. Single versus double intrauterine insemination (IUI) for pregnancy: A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2017; 215:75.</a></li><li><a class="nounderline abstract_t">Rakic L, Kostova E, Cohlen BJ, Cantineau AE. Double versus single intrauterine insemination (IUI) in stimulated cycles for subfertile couples. Cochrane Database Syst Rev 2021; 7:CD003854.</a></li><li><a class="nounderline abstract_t">van der Poel N, Farquhar C, Abou-Setta AM, et al. Soft versus firm catheters for intrauterine insemination. Cochrane Database Syst Rev 2010; :CD006225.</a></li><li><a class="nounderline abstract_t">Lavie O, Margalioth EJ, Geva-Eldar T, Ben-Chetrit A. Ultrasonographic endometrial changes after intrauterine insemination: a comparison of two catheters. Fertil Steril 1997; 68:731.</a></li><li><a class="nounderline abstract_t">Settlage DS, Motoshima M, Tredway DR. Sperm transport from the external cervical os to the fallopian tubes in women: a time and quantitation study. Fertil Steril 1973; 24:655.</a></li><li><a class="nounderline abstract_t">Saleh A, Tan SL, Biljan MM, Tulandi T. A randomized study of the effect of 10 minutes of bed rest after intrauterine insemination. Fertil Steril 2000; 74:509.</a></li><li><a class="nounderline abstract_t">van Rijswijk J, Caanen MR, Mijatovic V, et al. Immobilization or mobilization after IUI: an RCT. Hum Reprod 2017; 32:2218.</a></li><li><a class="nounderline abstract_t">Hill MJ, Whitcomb BW, Lewis TD, et al. Progesterone luteal support after ovulation induction and intrauterine insemination: a systematic review and meta-analysis. Fertil Steril 2013; 100:1373.</a></li><li><a class="nounderline abstract_t">Smith JF, Eisenberg ML, Millstein SG, et al. Fertility treatments and outcomes among couples seeking fertility care: data from a prospective fertility cohort in the United States. Fertil Steril 2011; 95:79.</a></li><li><a class="nounderline abstract_t">Haagen EC, Hermens RP, Nelen WL, et al. Subfertility guidelines in Europe: the quantity and quality of intrauterine insemination guidelines. Hum Reprod 2006; 21:2103.</a></li></ol></div><div id="topicVersionRevision">Topic 7413 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16169402" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Effect of ejaculatory abstinence period on the pregnancy rate after intrauterine insemination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19732887" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A short period of ejaculatory abstinence before intrauterine insemination is associated with higher pregnancy rates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17509584" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Effect of vaginal lubricants on sperm motility and chromatin integrity: a prospective comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9886513" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The effects of coital lubricants on sperm motility in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31612995" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Semen preparation techniques for intrauterine insemination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12801569" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Efficacy and pregnancy outcome of two methods of semen preparation for intrauterine insemination: a prospective randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10530401" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Relationship of total motile sperm count and percentage motile sperm to successful pregnancy rates following intrauterine insemination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15374704" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Performance of the postwash total motile sperm count as a predictor of pregnancy at the time of intrauterine insemination: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11287015" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Effect of the total motile sperm count on the efficacy and cost-effectiveness of intrauterine insemination and in vitro fertilization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12350496" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Processed total motile sperm count correlates with pregnancy outcome after intrauterine insemination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8825169" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The impact of the total motile sperm count on the success of intrauterine insemination with husband's spermatozoa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15243004" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Influence of the number of motile spermatozoa inseminated and of their morphology on the success of intrauterine insemination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35487770" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Comprehensive guidance for human embryology, andrology, and endocrinology laboratories: management and operations: a committee opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34250273" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The Maribor consensus: report of an expert meeting on the development of performance indicators for clinical practice in ART.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31486806" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The Vienna consensus: report of an expert meeting on the development of art laboratory performance indicators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31486806" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The Vienna consensus: report of an expert meeting on the development of art laboratory performance indicators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31486806" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The Vienna consensus: report of an expert meeting on the development of art laboratory performance indicators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37290111" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Intrauterine Insemination After Human Chorionic Gonadotropin Trigger or Luteinizing Hormone Surge: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20393953" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Synchronised approach for intrauterine insemination in subfertile couples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15236980" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : One versus two inseminations per cycle in intrauterine insemination with sperm from patients' husbands: a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20457669" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Single versus double intrauterine insemination in multi-follicular ovarian hyperstimulation cycles: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21710180" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Timing of intrauterine insemination: an attempt to unravel the enigma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19782353" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Comparison of the effectiveness of single versus double intrauterine insemination with three different timing regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22796236" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Spontaneous triggering of ovulation versus HCG administration in patients undergoing IUI: a prospective randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17110396" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A randomized clinical trial of clomiphene citrate versus low dose recombinant FSH for ovarian hyperstimulation in intrauterine insemination cycles for unexplained and male subfertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26398071" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Letrozole, Gonadotropin, or Clomiphene for Unexplained Infertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29778386" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Ovarian stimulation in infertile women treated with the use of intrauterine insemination: a cohort study from China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18692823" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Clomiphene citrate or aromatase inhibitors for superovulation in women with unexplained infertility undergoing intrauterine insemination: a prospective randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effect of letrozole versus clomiphene on live birth in women with anovulatory infertility due to PCOS: a randomized double-blind multicenter trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22972053" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Intra-uterine insemination for unexplained subfertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19531445" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A randomized clinical trial to evaluate optimal treatment for unexplained infertility: the fast track and standard treatment (FASTT) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17173907" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Human chorionic gonadotropin administration vs. luteinizing monitoring for intrauterine insemination timing, after administration of clomiphene citrate: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12151445" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Ovarian stimulation in intrauterine insemination with donor sperm: a randomized study comparing clomiphene citrate in fixed protocol versus highly purified urinary FSH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21429486" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Recombinant FSH versus highly purified FSH in intrauterine insemination: systematic review and metaanalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12909495" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Follicular response and pregnancy among infertile women undergoing ovulation induction and intrauterine insemination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1906408" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Follicular size at the time of human chorionic gonadotropin administration predicts ovulation outcome in human menopausal gonadotropin-stimulated cycles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22459633" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : What is the optimal follicular size before triggering ovulation in intrauterine insemination cycles with clomiphene citrate or letrozole? An analysis of 988 cycles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20218821" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The association between follicular size on human chorionic gonadotropin day and pregnancy rate in clomiphene citrate treated polycystic ovary syndrome patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21334613" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Role of gonadotropin-releasing hormone antagonist in the management of subfertile couples with intrauterine insemination and controlled ovarian stimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17678911" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Multifollicular recruitment in combination with gonadotropin-releasing hormone antagonist increased pregnancy rates in intrauterine insemination cycles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16500321" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Use of gonadotropin-releasing hormone antagonists to overcome the drawbacks of intrauterine insemination on weekends.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28605667" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Single versus double intrauterine insemination (IUI) for pregnancy: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34260059" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Double versus single intrauterine insemination (IUI) in stimulated cycles for subfertile couples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21069687" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Soft versus firm catheters for intrauterine insemination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9341621" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Ultrasonographic endometrial changes after intrauterine insemination: a comparison of two catheters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4737661" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Sperm transport from the external cervical os to the fallopian tubes in women: a time and quantitation study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10973647" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A randomized study of the effect of 10 minutes of bed rest after intrauterine insemination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29040538" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Immobilization or mobilization after IUI: an RCT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23876537" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Progesterone luteal support after ovulation induction and intrauterine insemination: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20659733" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Fertility treatments and outcomes among couples seeking fertility care: data from a prospective fertility cohort in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16601007" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Subfertility guidelines in Europe: the quantity and quality of intrauterine insemination guidelines.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
